Cryo-EM structure of the fully-loaded asymmetric anthrax lethal toxin in its heptameric pre-pore state.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
08 2020
Historique:
received: 05 04 2020
accepted: 27 06 2020
revised: 01 09 2020
pubmed: 19 8 2020
medline: 23 9 2020
entrez: 19 8 2020
Statut: epublish

Résumé

Anthrax toxin is the major virulence factor secreted by Bacillus anthracis, causing high mortality in humans and other mammals. It consists of a membrane translocase, known as protective antigen (PA), that catalyzes the unfolding of its cytotoxic substrates lethal factor (LF) and edema factor (EF), followed by translocation into the host cell. Substrate recruitment to the heptameric PA pre-pore and subsequent translocation, however, are not well understood. Here, we report three high-resolution cryo-EM structures of the fully-loaded anthrax lethal toxin in its heptameric pre-pore state, which differ in the position and conformation of LFs. The structures reveal that three LFs interact with the heptameric PA and upon binding change their conformation to form a continuous chain of head-to-tail interactions. As a result of the underlying symmetry mismatch, one LF binding site in PA remains unoccupied. Whereas one LF directly interacts with a part of PA called α-clamp, the others do not interact with this region, indicating an intermediate state between toxin assembly and translocation. Interestingly, the interaction of the N-terminal domain with the α-clamp correlates with a higher flexibility in the C-terminal domain of the protein. Based on our data, we propose a model for toxin assembly, in which the relative position of the N-terminal α-helices in the three LFs determines which factor is translocated first.

Identifiants

pubmed: 32810181
doi: 10.1371/journal.ppat.1008530
pii: PPATHOGENS-D-20-00680
pmc: PMC7462287
doi:

Substances chimiques

Antigens, Bacterial 0
Bacterial Toxins 0
anthrax toxin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008530

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Science. 1998 May 1;280(5364):734-7
pubmed: 9563949
J Struct Biol. 2013 Nov;184(2):261-70
pubmed: 23999189
J Struct Biol. 2019 Jan 1;205(1):30-40
pubmed: 30502495
Ultramicroscopy. 2014 May;140:9-19
pubmed: 24562077
Toxins (Basel). 2016 Mar 10;8(3):
pubmed: 26978402
J Mol Biol. 2004 Nov 26;344(3):739-56
pubmed: 15533442
Nature. 2015 May 28;521(7553):545-9
pubmed: 25778700
Eur J Cell Biol. 2004 Jul;83(6):281-8
pubmed: 15511085
Biochemistry. 1999 Aug 10;38(32):10432-41
pubmed: 10441138
J Mol Biol. 2009 Sep 25;392(3):614-29
pubmed: 19627991
Proc Natl Acad Sci U S A. 1982 May;79(10):3162-6
pubmed: 6285339
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9932-7
pubmed: 23716698
J Biol Chem. 1994 Aug 12;269(32):20607-12
pubmed: 8051159
Nat Struct Mol Biol. 2010 Nov;17(11):1383-90
pubmed: 21037566
Protein Sci. 2013 May;22(5):586-94
pubmed: 23494942
Biochem Biophys Res Commun. 2004 Sep 10;322(1):258-62
pubmed: 15313199
Nature. 1997 Feb 27;385(6619):833-8
pubmed: 9039918
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Gen Physiol. 2016 Oct;148(4):313-24
pubmed: 27670897
J Mol Biol. 2010 Jun 25;399(5):741-58
pubmed: 20433851
EMBO J. 2005 Mar 9;24(5):929-41
pubmed: 15719022
J Vis Exp. 2017 May 16;(123):
pubmed: 28570515
Mol Microbiol. 2011 Sep;81(5):1390-401
pubmed: 21797942
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13147-51
pubmed: 15326297
Infect Immun. 1985 Jan;47(1):306-10
pubmed: 3917427
Structure. 2004 Nov;12(11):2059-66
pubmed: 15530370
Annu Rev Cell Dev Biol. 2002;18:1-24
pubmed: 12142266
Biochemistry. 2000 Jun 6;39(22):6706-13
pubmed: 10828989
J Cell Biol. 2003 Feb 3;160(3):321-8
pubmed: 12551953
Nature. 2001 Nov 8;414(6860):225-9
pubmed: 11700562
PLoS Pathog. 2010 Mar 05;6(3):e1000792
pubmed: 20221438
Nature. 2001 Nov 8;414(6860):229-33
pubmed: 11700563
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Protein Sci. 2006 Sep;15(9):2190-200
pubmed: 16943448
PLoS One. 2010 Nov 08;5(11):e13888
pubmed: 21079738
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10277-81
pubmed: 1438214
J Biol Chem. 1986 Jun 5;261(16):7123-6
pubmed: 3711080
Nature. 2002 Jan 24;415(6870):396-402
pubmed: 11807546
Nat Commun. 2020 Feb 11;11(1):840
pubmed: 32047164
Sci Rep. 2016 Mar 21;6:23346
pubmed: 26996161
Nature. 2004 Aug 19;430(7002):905-8
pubmed: 15243628
Commun Biol. 2019 Jun 19;2:218
pubmed: 31240256
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5170-4
pubmed: 12700348
Biochemistry. 2004 May 25;43(20):6339-43
pubmed: 15147218
J Mol Model. 2016 Jan;22(1):7
pubmed: 26659402
Science. 2005 Jul 29;309(5735):777-81
pubmed: 16051798
J Biol Chem. 2012 Dec 21;287(52):43753-64
pubmed: 23115233
Protein Sci. 2013 Apr;22(4):492-501
pubmed: 23389868

Auteurs

Claudia Antoni (C)

Department of Structural Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany.

Dennis Quentin (D)

Department of Structural Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany.

Alexander E Lang (AE)

Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Klaus Aktories (K)

Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Christos Gatsogiannis (C)

Department of Structural Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany.

Stefan Raunser (S)

Department of Structural Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH